Male pattern baldness and prostate cancer risk in a population-based case-control study

Cancer Epidemiology

Volumn 34, Issue 2, 2010, Pages 131-135

  Wright, Jonathan L ^a,b   Page, Stephanie T ^a   Lin, Daniel W ^a,b   Stanford, Janet L ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Male pattern baldness; Population based; Prostate cancer; Relative risk

Indexed keywords

ANDROGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; HAIR; HAIR LOSS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; ONSET AGE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; STATISTICAL SIGNIFICANCE; ALOPECIA; CASE CONTROL STUDY; MIDDLE AGED; POPULATION GROUP; PROSTATIC NEOPLASMS; RISK; UNITED STATES;

ADULT; AGED; ALOPECIA; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION GROUPS; PROSTATIC NEOPLASMS; RISK; WASHINGTON;

EID: 77950297265     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.02.003     Document Type: Article

References (34)

1. Ellis J.A., Sinclair R., and Harrap S.B. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 4 22 (2002) 1-11
2. Nyholt D.R., Gillespie N.A., Heath A.C., and Martin N.G. Genetic basis of male pattern baldness. J Invest Dermatol 121 6 (2003) 1561-1564
3. Ellis J.A., Stebbing M., and Harrap S.B. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 116 3 (2001) 452-455
4. Hayes V.M., Severi G., Eggleton S.A., Padilla E.J., Southey M.C., Sutherland R.L., et al. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 14 4 (2005) 993-996
5. Hillmer A.M., Brockschmidt F.F., Hanneken S., Eigelshoven S., Steffens M., Flaquer A., et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 40 11 (2008) 1279-1281
6. Richards J.B., Yuan X., Geller F., Waterworth D., Bataille V., Glass D., et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 40 11 (2008) 1282-1284
7. Bang H.J., Yang Y.J., Lho D.S., Lee W.Y., Sim W.Y., and Chung B.C. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci 34 1 (2004) 11-16
8. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327 17 (1992) 1185-1191
9. Delongchamps N.B., Singh A., and Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13 3 (2006) 158-168
10. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 3 (2003) 215-224
11. Demark-Wahnefried W., Lesko S.M., Conoway M.R., RObertson C.N., Clark R.V., Lobaugh B., et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 18 5 (1997) 495-500
12. Denmark-Wahnefried W., Schildkraut J.M., Thompson D., Lesko S.M., McIntyre L., Schwingl P., et al. Early onset baldness and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 9 3 (2000) 325-328
13. Giles G.G., Severi G., Sinclair R., English D.R., McCredie M.R., Johnson W., et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 11 6 (2002) 549-553
14. Hawk E., Breslow R.A., and Graubard B.I. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 9 5 (2000) 523-527
15. Agalliu I., Salinas C.A., Hansten P.D., Ostrander E.A., and Stanford J.L. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168 3 (2008) 250-260
16. Ries L., Melbert D., Krapcho M., Stinchcomb D., Howlader N., Horner M., et al. SEER cancer statistics review, 1975-2005, based on November 2007 SEER data submission, posted to the SEER web site (2008), Institute NC, Bethesda, MD
17. Harman S.M., Metter E.J., Tobin J.D., Pearson J., and Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men, Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86 2 (2001) 724-731
18. Hayes V.M., Severi G., Padilla E.J., Morris H.A., Tilley W.D., Southey M.C., et al. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer 120 4 (2007) 776-780
19. Sawaya M.E., and Price V.H. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109 3 (1997) 296-300
20. Choi M.H., Yoo Y.S., and Chung B.C. Biochemical roles of testosterone and epitestosterone to 5 alpha-reductase as indicators of male-pattern baldness. J Invest Dermatol 116 1 (2001) 57-61
21. Camacho F.M., Garcia-Hernandez M.J., and Fernandez-Crehuet J.L. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. Br J Dermatol 158 5 (2008) 1121-1124
22. Ryu H.K., Kim K.M., Yoo E.A., Sim W.Y., and Chung B.C. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol 154 4 (2006) 730-734
23. Cunha G.R., Ricke W., Thomson A., Marker P.C., Risbridger G., Hayward S.W., et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92 4 (2004) 221-236
24. Keller E.T., Ershler W.B., and Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci 1 (1996) d59-d71
25. Imperato-McGinley J., and Zhu Y.S. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 198 1-2 (2002) 51-59
26. Zhu Y.S., and Sun G.H. 5alpha-Reductase isozymes in the prostate. J Med Sci 25 1 (2005) 1-12
27. Kaufman K.D., Olsen E.A., Whiting D., Savin R., DeVillez R., Bergfeld W., et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 39 4 Pt 1 (1998) 578-589
28. Chen W., Yang C.C., Chen G.Y., Wu M.C., Sheu H.M., and Tzai T.S. Patients with a large prostate show a higher prevalence of androgenetic alopecia. Arch Dermatol Res 296 6 (2004) 245-249
29. Oh B.R., Kim S.J., Moon J.D., Kim H.N., Kwon D.D., Won Y.H., et al. Association of benign prostatic hyperplasia with male pattern baldness. Urology 51 5 (1998) 744-748
30. Barrett-Connor E., Garland C., McPhillips J.B., Khaw K.T., and Wingard D.L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 50 1 (1990) 169-173
31. Mohr B.A., Feldman H.A., Kalish L.A., Longcope C., and McKinlay J.B. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 57 5 (2001) 930-935
32. Roddam A.W., Allen N.E., Appleby P., and Key T.J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100 3 (2008) 170-183
33. Norman R.W., Coakes K.E., Wright A.S., and Rittmaster R.S. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 150 5 Pt 2 (1993) 1736-1739
34. Taylor R., Matassa J., Leavy J.E., and Fritschi L. Validity of self reported male balding patterns in epidemiological studies. BMC Public Health 4 (2004) 60